Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
10:11am, Thursday, 02'nd May 2024
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago.
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
08:00am, Thursday, 02'nd May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
10:20am, Tuesday, 30'th Apr 2024
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader of the multi-regional part
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:07am, Thursday, 25'th Apr 2024
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
08:00am, Thursday, 18'th Apr 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
Levi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNY
07:25am, Wednesday, 17'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
07:20am, Thursday, 11'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation
07:25am, Wednesday, 10'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
07:30am, Tuesday, 09'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
09:46am, Monday, 08'th Apr 2024
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY
07:20am, Monday, 08'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the
NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v
